5. Tanstuzumab Treatment for Breast Cancer
スポンサーリンク
概要
著者
-
Hatake Kiyohiko
Division Of Medical Oncology Cancer Institute Hospital
-
TOKUDOME Nahomi
Division of Medical Oncology, Cancer Institute Hospital
-
Ito Yoshinori
Division Of Central Clinical Laboratory Nagoya City University Hospital
-
Hatake Kiyohiko
Division of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research
-
Tokudome Nahomi
Division of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research
関連論文
- Increased incidence of interstitial pneumonia by CHOP combined with rituximab
- A Case of Acute Promyelocytic Leukemia during Gefitinib Treatment
- Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer : cross-resistance to capecitabine
- Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients
- Does Lapatinib, a Small-Molecule Tyrosine Kinase Inhibitor, Constitute a Breakthrough in the Treatment of Breast Cancer?
- Efficacy and Safety of Combined Trastuzumab and Paclitaxel Therapy as a Second-Line Treatment in Women with Metastatic Breast Cancer : A Single Institutional Experience
- High Prevalence of HER-2/neu and p53 Overexpression in Inflammatory Breast Cancer
- Severe Infusion Reaction Induced by Trastuzumab : A Case Report
- High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families
- Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer
- Next Generation Molecular Targeted Agents for Breast Cancer : Focus on EGFR and VEGFR Pathways
- Chemotherapy for Small-Bowel Adenocarcinoma at a Single Institution
- Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors
- Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan
- Continuous treatment of bestatin induces anti-angiogenic property in endothelial cells
- Differential Regulation of Eotaxin-1/CCL11 and Eotaxin-3/CCL26 Production by the TNF-α and IL-4 Stimulated Human Lung Fibroblast(Pharmacology)
- Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab
- Gene Therapy for Breast Cancer.-Review of Clinical Gene Therapy Trials for Breast Cancer and MDR1 Gene Therapy Trial in Cancer Institute Hospital
- No CD117 expression on B progenitors in the regenerating bone marrow
- Rare but important adverse effects of all-trans retinoic acid in acute promyelocytic leukemia and their management
- Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph^1-positive chronic myelogenous leukemia
- Short-course palliative radiotherapy for airway stenosis in non-small cell lung cancer
- Functional in vivo optical imaging of tumor angiogenesis, growth, and metastasis prevented by administration of anti-human VEGF antibody in xenograft model of human fibrosarcoma HT1080 cells
- Current therapeutic strategies for anal squamous cell carcinoma in Japan
- Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes
- Complete Resection After Imatinib Treatment of a Gastrointestinal Stromal Tumor of the Ileum with Peritoneal Metastases : Report of a Case
- High stability of enzyme immunoassay for hepatitis C virus core antigen-evaluation before and after incubation at room temperature
- Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
- Dlk-1, a cell surface antigen on foetal hepatic stem/progenitor cells, is expressed in hepatocellular, colon, pancreas and breast carcinomas at a high frequency
- Anal Canal Carcinoma with Pagetoid Spread : Report of a Case
- Hematological abnormalities in a patient with a 22q11.2 deletion
- Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer
- Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer
- Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients
- Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients
- Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane
- Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors
- 5. Tanstuzumab Treatment for Breast Cancer